Citicoline, use in cognitive decline: Vascular and degenerative

• Published in: Journal of the neurological sciences 2010-12, Vol.299 (1), p.188-192
• Main Authors: García-Cobos, Rocío, Frank-García, Ana, Gutiérrez-Fernández, María, Díez-Tejedor, Exuperio
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Biological and medical sciences; Citicoline; Clinical trials; Cognition Disorders - drug therapy; Cognitive impairment; Cytidine Diphosphate Choline - therapeutic use; Dementia; Dementia - drug therapy; Disease Models, Animal; Humans; Medical sciences; Neurology; Nootropic Agents - therapeutic use; Stroke; Vascular diseases and vascular malformations of the nervous system
• ISSN: 0022-510X; 1878-5883
• DOI: 10.1016/j.jns.2010.08.027

Abstract CDP-choline has been widespread used in humans for decades as a treatment for many types of cognitive impairment. Despite this, its mechanism of action still remains unclear, but several experimental models in acute cerebral ischaemia suggest that it could have a brain repair action. Due to the lack of significant adverse effects and its high tolerability, there has been a growing interest for this molecule in recent years. In this article, a review of the most significant published clinical trials in cognitive decline has been made. A few Citicoline trials have studied its effects at medium and long-term on vascular cognitive impairment and Alzheimer's disease. Results show that Citicoline seems to have beneficial impact on several cognitive domains, but the methodological heterogeneity of the these studies makes it difficult to draw conclusions about these effects. New trials with a greater number of patients, uniform diagnostic criteria for inclusion and standardized neuropsychological assessment are needed to evidence with much more consistency Citicoline efficacy upon cognitive disorders. The use of new neuroimaging procedures in current trials could be of great interest.